|
| Saturday, June 21, 2025 |
|
|
康希諾重磅推出優佩欣疫苗 為兒童健康保駕護航的創新之選 |
| 在看似平靜的日常生活中，一種名為「肺炎球菌」的細菌正悄然威脅著兒童的健康。這種在人體鼻咽部「潛伏」的條件致病菌，平時可能毫無症狀，但一旦免疫力下降便會興風作浪，引發一系列疾病。 more info >> |
|
| Friday, June 20, 2025 |
|
|
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health |
| Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single largest infectious cause of death in children worldwide. more info >> |
|
|
康希诺重磅推出优佩欣疫苗 为儿童健康保驾护航的创新之选 |
| 在看似平静的日常生活中，一种名为“肺炎球菌”的细菌正悄然威胁着儿童的健康。这种在人体鼻咽部“潜伏”的条件致病菌，平时可能毫无症状，但一旦免疫力下降便会兴风作浪，引发一系列疾病。 more info >> |
|
| Tuesday, March 25, 2025 |
|
|
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong |
| CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, 'CanSinoBIO' or the 'Company'), a leading player in China's vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities. more info >> |
|
|
收入狂飙同比增长137% 多款产品蓄势以待 康希诺增长动能充沛 |
| 康希诺生物股份公司（股份代码：688185.SH和6185.HK，以下简称：康希诺）作为中国疫苗领域的佼佼者，凭借持续的研发创新和强大的商业化能力，在2024年实现了显著的业绩增长。 more info >> |
|
| Wednesday, October 9, 2024 |
|
|
CanSino Receives Another Strong Boost |
| CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio. more info >> |
|
| Thursday, August 29, 2024 |
|
|
CanSinoBIO Reports Outstanding H1 2024 Performance |
| CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. more info >> |
|
|
康希諾生物2024上半年業績亮眼：流腦疫苗引領增長，加快合作與國際化步伐 |
| 康希諾生物今日披露了2024年上半年業績報告，營收達到3.03億元，其中流腦結合疫苗家族再度展現强勁增長動力，尤其是ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）（以下簡稱“MCV4”）曼海欣®作爲亞洲首個腦膜炎球菌四價結合疫苗産品，不僅填補了市場空白，更爲我國嬰幼兒流腦疾病預防樹立了新標杆。 more info >> |
|
|
康希诺生物2024上半年业绩亮眼：流脑疫苗引领增长，加快合作与国际化步伐 |
| 康希诺生物今日披露了2024年上半年业绩报告，营收达到3.03亿元，其中流脑结合疫苗家族再度展现强劲增长动力，尤其是ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称“MCV4”）曼海欣®作为亚洲首个脑膜炎球菌四价结合疫苗产品，不仅填补了市场空白，更为我国婴幼儿流脑疾病预防树立了新标杆。 more info >> |
|
| Friday, April 26, 2024 |
|
|
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine |
| On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province. more info >> |
|
|
|
|
